|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pernicová Z, Slabáková E, Kharaishvili G,
Bouchal J, Král M, Kunická Z, Machala M, Kozubík A and Souček K:
Androgen depletion induces senescence in prostate cancer cells
through down-regulation of Skp2. Neoplasia. 13:526–536. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Takeda M, Mizokami A, Mamiya K, Li YQ,
Zhang J, Keller ET and Namiki M: The establishment of two
paclitaxel-resistant prostate cancer cell lines and the mechanisms
of paclitaxel resistance with two cell lines. Prostate. 67:955–967.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fujita Y, Kojima K, Ohhashi R, Hamada N,
Nozawa Y, Kitamoto A, Sato A, Kondo S, Kojima T, Deguchi T, et al:
MiR-148a attenuates paclitaxel resistance of hormone-refractory,
drug-resistant prostate cancer PC3 cells by regulating MSK1
expression. J Biol Chem. 285:19076–19084. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wei W, Ayad NG, Wan Y, Zhang GJ, Kirschner
MW and Kaelin WG Jr: Degradation of the SCF component Skp2 in
cell-cycle phase G1 by the anaphase-promoting complex. Nature.
428:194–198. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang Z, Gao D, Fukushima H, Inuzuka H, Liu
P, Wan L, Sarkar FH and Wei W: Skp2: A novel potential therapeutic
target for prostate cancer. Biochim Biophys Acta. 1825:11–17.
2012.
|
|
7
|
Drobnjak M, Melamed J, Taneja S, Melzer K,
Wieczorek R, Levinson B, Zeleniuch-Jacquotte A, Polsky D, Ferrara
J, Perez-Soler R, et al: Altered expression of p27 and Skp2
proteins in prostate cancer of African-American patients. Clin
Cancer Res. 9:2613–2619. 2003.PubMed/NCBI
|
|
8
|
Shim EH, Johnson L, Noh HL, Kim YJ, Sun H,
Zeiss C and Zhang H: Expression of the F-box protein SKP2 induces
hyperplasia, dysplasia, and low-grade carcinoma in the mouse
prostate. Cancer Res. 63:1583–1588. 2003.PubMed/NCBI
|
|
9
|
Lin HK, Chen Z, Wang G, Nardella C, Lee
SW, Chan CH, Yang WL, Wang J, Egia A, Nakayama KI, et al: Skp2
targeting suppresses tumorigenesis by Arf-p53-independent cellular
senescence. Nature. 464:374–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang Q, Huang J, Wu Q, Cai Y, Zhu L, Lu X,
Chen S, Chen C and Wang Z: Acquisition of epithelial-mesenchymal
transition is associated with Skp2 expression in
paclitaxel-resistant breast cancer cells. Br J Cancer.
110:1958–1967. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Davidovich S, Ben-Izhak O, Shapira M,
Futerman B and Hershko DD: Over-expression of Skp2 is associated
with resistance to preoperative doxorubicin-based chemotherapy in
primary breast cancer. Breast Cancer Res. 10:R632008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chan CH, Li CF, Yang WL, Gao Y, Lee SW,
Feng Z, Huang HY, Tsai KK, Flores LG, Shao Y, et al: The Skp2-SCF
E3 ligase regulates Akt ubiquitination, glycolysis, herceptin
sensitivity, and tumorigenesis. Cell. 149:1098–1111. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li Y, Mizokami A, Izumi K, Narimoto K,
Shima T, Zhang J, Dai J, Keller ET and Namiki M: CTEN/tensin 4
expression induces sensitivity to paclitaxel in prostate cancer.
Prostate. 70:48–60. 2010. View Article : Google Scholar
|
|
14
|
Statkiewicz M, Maryan N, Lipiec A, Grecka
E, Grygorowicz MA, Omiotek M, Gorska A, Mikula M and Malecki M: The
role of the SHH gene in prostate cancer cell resistance to
paclitaxel. Prostate. 74:1142–1152. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Singh S, Chitkara D, Mehrazin R, Behrman
SW, Wake RW and Mahato RI: Chemoresistance in prostate cancer cells
is regulated by miRNAs and Hedgehog pathway. PLoS One.
7:e400212012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li D, Zhao LN, Zheng XL, Lin P, Lin F, Li
Y, Zou HF, Cui RJ, Chen H and Yu XG: Sox2 is involved in paclitaxel
resistance of the prostate cancer cell line PC-3 via the PI3K/Akt
pathway. Mol Med Rep. 10:3169–3176. 2014.PubMed/NCBI
|
|
17
|
Kojima K, Fujita Y, Nozawa Y, Deguchi T
and Ito M: MiR-34a attenuates paclitaxel-resistance of
hormone-refractory prostate cancer PC3 cells through direct and
indirect mechanisms. Prostate. 70:1501–1512. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim JJ, Yin B, Christudass CS, Terada N,
Rajagopalan K, Fabry B, Lee DY, Shiraishi T, Getzenberg RH, Veltri
RW, et al: Acquisition of paclitaxel resistance is associated with
a more aggressive and invasive phenotype in prostate cancer. J Cell
Biochem. 114:1286–1293. 2013. View Article : Google Scholar
|
|
19
|
Sarikas A, Hartmann T and Pan ZQ: The
cullin protein family. Genome Biol. 12:220–232. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang X, Li L, Liang Y, Li C, Zhao H, Ye D,
Sun M, Jeong LS, Feng Y, Fu S, et al: Targeting the neddylation
pathway to suppress the growth of prostate cancer cells:
Therapeutic implication for the men's cancer. Biomed Res Int.
2014:9743092014.PubMed/NCBI
|
|
21
|
Inuzuka H, Gao D, Finley LW, Yang W, Wan
L, Fukushima H, Chin YR, Zhai B, Shaik S, Lau AW, et al:
Acetylation-dependent regulation of Skp2 function. Cell.
150:179–193. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li P, Yang R and Gao WQ: Contributions of
epithelial-mesenchymal transition and cancer stem cells to the
development of castration resistance of prostate cancer. Mol
Cancer. 13:552014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sun Y, Wang BE, Leong KG, Yue P, Li L,
Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, et al: Androgen
deprivation causes epithelial-mesenchymal transition in the
prostate: Implications for androgen-deprivation therapy. Cancer
Res. 72:527–536. 2012. View Article : Google Scholar
|
|
24
|
Kajiyama H, Shibata K, Terauchi M,
Yamashita M, Ino K, Nawa A and Kikkawa F: Chemoresistance to
paclitaxel induces epithelial-mesenchymal transition and enhances
metastatic potential for epithelial ovarian carcinoma cells. Int J
Oncol. 31:277–283. 2007.PubMed/NCBI
|
|
25
|
Zhao H, Bauzon F, Fu H, Lu Z, Cui J,
Nakayama K, Nakayama KI, Locker J and Zhu L: Skp2 deletion unmasks
a p27 safeguard that blocks tumorigenesis in the absence of pRb and
p53 tumor suppressors. Cancer Cell. 24:645–659. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zheng XY, Ding W, Xie LP and Chen ZD:
Correlation of Skp2 and P27kip1 protein expression and
clinicopathological features of prostate cancer. Ai Zheng.
23:215–218. 2004.In Chinese. PubMed/NCBI
|
|
27
|
Nakayama K, Nagahama H, Minamishima YA,
Matsumoto M, Nakamichi I, Kitagawa K, Shirane M, Tsunematsu R,
Tsukiyama T, Ishida N, et al: Targeted disruption of Skp2 results
in accumulation of cyclin E and p27(Kip1), polyploidy and
centrosome overduplication. EMBO J. 19:2069–2081. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu L: Skp2 knockout reduces cell
proliferation and mouse body size: And prevents cancer? Cell Res.
20:605–607. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ben-Izhak O, Lahav-Baratz S, Meretyk S,
Ben-Eliezer S, Sabo E, Dirnfeld M, Cohen S and Ciechanover A:
Inverse relationship between Skp2 ubiquitin ligase and the cyclin
dependent kinase inhibitor p27Kip1 in prostate cancer. J Urol.
170:241–245. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Le TV, Seo Y, Ryu CJ, Lee HR and Park HJ:
Increased expression of p27 is associated with the cisplatin
resistance in gastric cancer cell line YCC-3. Arch Pharm Res.
33:1127–1132. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhao YF, Zhao JY, Yue H, Hu KS, Shen H,
Guo ZG and Su XJ: FOXD1 promotes breast cancer proliferation and
chemotherapeutic drug resistance by targeting p27. Biochem Biophys
Res Commun. 456:232–237. 2015. View Article : Google Scholar
|
|
32
|
Chan CH, Morrow JK, Li CF, Gao Y, Jin G,
Moten A, Stagg LJ, Ladbury JE, Cai Z, Xu D, et al: Pharmacological
inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem
cell traits and cancer progression. Cell. 154:556–568. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chan CH, Morrow JK, Zhang S and Lin HK:
Skp2: A dream target in the coming age of cancer therapy. Cell
Cycle. 13:679–680. 2014. View Article : Google Scholar : PubMed/NCBI
|
